Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Oct 7, 2022; 28(37): 5444-5456
Published online Oct 7, 2022. doi: 10.3748/wjg.v28.i37.5444
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flowchart of participants in both cohorts. COVID: Coronavirus disease 2019; CT: Computed tomography; HIV: Human Immunodeficiency virus.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Area under the receiver operating characteristic curve for the LFN-coronavirus disease 2019 index to predict mortality. A: Patients with metabolic associated fatty liver disease and coronavirus disease 2019; B: Patients without metabolic associated fatty liver disease and coronavirus disease 2019. MAFLD: Metabolic associated fatty liver disease; COVID-19: Coronavirus disease 2019; LFN: Liver fibrosis and nutrition.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Kaplan-Meier curve for 28-d mortality according to the LFN-coronavirus disease 2019 index. MAFLD: Metabolic associated fatty liver disease; COVID-19: Coronavirus disease 2019; LFN: Liver fibrosis and nutrition.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Adjusted mortality analysis (Cox regression) for 28-d mortality according to LFN-coronavirus disease 2019 index. COVID-19: Coronavirus disease 2019; LFN: Liver fibrosis and nutrition.
  • Citation: Macías-Rodríguez RU, Solís-Ortega AA, Ornelas-Arroyo VJ, Ruiz-Margáin A, González-Huezo MS, Urdiales-Morán NA, Román-Calleja BM, Mayorquín-Aguilar JM, González-Regueiro JA, Campos-Murguía A, Toledo-Coronado IV, Chapa-Ibargüengoitia M, Valencia-Peña B, Martínez-Cabrera CF, Flores-García NC. Prognostic performance of an index based on lactic dehydrogenase and transaminases for patients with liver steatosis and COVID-19. World J Gastroenterol 2022; 28(37): 5444-5456
  • URL: https://www.wjgnet.com/1007-9327/full/v28/i37/5444.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v28.i37.5444